Key result
Newborn screening for classic isovaleric aciduria significantly reduced mortality to 1.1% compared to 10.9% in unscreened individuals, alongside significant reductions in neurological symptoms and developmental delay.
Why the study?
Classic isovaleric aciduria causes recurrent life-threatening decompensations and neurocognitive impairment, but the impact of early diagnosis on mortality and neurocognitive outcome needed evaluation.
Does early diagnosis through newborn screening improve survival and neurocognitive outcomes in individuals with classic isovaleric aciduria?
Meta-Analysis (n=240)
Yes
Does early diagnosis through newborn screening improve survival and neurocognitive outcomes in individuals with classic isovaleric aciduria?
Early diagnosis of classic isovaleric aciduria through newborn screening significantly reduces mortality and improves neurocognitive outcomes.
Answers are grounded in this paper and cite their sources.
Supports newborn screening for isovaleric aciduria; confirms mortality and neurodevelopmental benefit in meta-analysis.
Purpose Classic isovaleric aciduria (cIVA) is a rare inherited metabolic disorder characterized by recurrent life-threatening metabolic decompensations and neurocognitive impairment in untreated patients. This meta-analysis aims to assess the impact of early diagnosis on mortality and neurocognitive outcome. Methods A systematic literature search for articles published until 2022 was conducted following PRISMA protocol guidelines. We investigated effects on clinical outcome and survival, analyzing outcome parameters using meta-analytical measures and estimating effect sizes with a random-effects model. Results Overall, 20 studies were included, reporting on 240 individuals with cIVA. Individuals identified by NBS presented with a lower frequency of neurological symptoms (13.0% versus 44.9%; P = 0.0040) and developmental delay (6.1% versus 51.2%; P < 0.0001), and had a lower mortality rate (1.1% versus 10.9%; P = 0.0320). The quality of national healthcare systems did not have a measurable impact on neurocognitive outcome and mortality. Despite the beneficial effect of NBS on clinical outcome and mortality, it could not reliably prevent the manifestation of neonatal decompensation in all individuals with cIVA identified by NBS. Conclusions Early diagnosis through NBS is essential for the timely initiation of therapy and for improving outcomes and survival rates in individuals with cIVA.
No takes yet. Share an insight, caveat, or question.
Reischl‐Hajiabadi et al. (2025) conducted a meta-analysis in Classic isovaleric aciduria (cIVA) (n=240). Newborn screening vs. Diagnosis after onset of symptoms was evaluated on Mortality rate (p=0.0320). Newborn screening for classic isovaleric aciduria significantly reduced mortality to 1.1% compared to 10.9% in unscreened individuals, alongside significant reductions in neurological symptoms and developmental delay.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: